Cancer stem cells (CSCs) are a subpopulation of tumour cells with the ability to initiate tumours as well as reconstitute the cellular heterogeneity typical of their tumours of origin ([@bib19]). CD44-positive fractions of gastric cancers (GCs) can generate spheroid colonies under non-adherent conditions, and small numbers of CD44-positive cells can generate tumours in severe combined immunodeficiency (SCID) mice ([@bib23]), indicating that CD44-expressing cancer cells include CSCs. Several reports have suggested that CSCs can initiate and facilitate cancer progression by inducing cancer metastasis and therapeutic resistance in GC, resulting in poor survival ([@bib13]; [@bib7]; [@bib29]).

CD44 is a family of transmembrane glycoprotein receptors that bind to hyaluronic acid, and the resultant intracellular signalling is linked to diverse cellular functions, including cell adhesion, migration, and invasion ([@bib10]; [@bib22]). The gene encoding the CD44 standard isoform (CD44s) consists of 20 exons, wherein the distal extracellular domain is responsible for binding to hyaluronic acid and the proximal extracellular domain is the site of alternative mRNA splicing, which results in multiple variant isoforms (CD44v2--v10) ([@bib22]). Among the variant isoforms, the roles of CD44 variant-6 (CD44v6) and CD44 variant-9 (CD44v9) are well-studied in GC. CD44v6-positive advanced GCs are associated with haematogenous metastasis, and the survival of CD44v6-positive patients is significantly poorer than that of CD44v6-negative patients ([@bib34]). CD44v9 interacts with and stabilises xCT, a glutamate-cystine transporter, resulting in increased intracellular levels of reduced glutathione. CD44v9-positive cells have an enhanced ability to suppress reactive oxygen species (ROS) production, resulting in the therapeutic resistance, recurrence, and metastasis of tumours ([@bib8]; [@bib26]; [@bib33]).

The invasive front of tumours has been proposed to contain important prognostic information owing to the lack of cohesiveness, secretion of proteolytic enzymes, reorganisation of the extracellular matrix, and increased cell proliferation ([@bib17]; [@bib21]).

However, no studies have evaluated CD44 expression at the invasive tumour front (ITF). Here, we examined the expression and localisation of CD44 isoforms in GC tissues to determine the association between the presence of cancer stem-like cells at the ITF and the prognosis of patients with resectable GC. In order to evaluate the prognostic significance of CD44 isoforms based on immunohistochemical analyses of whole-tumour sections and the ITF, the primary end points were disease-specific survival and patterns of relapse in resectable GC patients, and the secondary end point was to stratify the survival risk of GC cases according to the prognostic analysis.

Materials and methods
=====================

Patients and study materials
----------------------------

One hundred and twenty-three primary gastric adenocarcinoma specimens were obtained from patients who underwent gastrectomy between January 2007 and December 2009 at the Shiga University of Medical Science Hospital, Japan. Specimens from patients with distant metastasis, peritoneal dissemination, or mucosal infiltration of the tumour (pT1(M)) were excluded. The histological type was determined as differentiated or undifferentiated; specifically, highly and moderately differentiated tubular or papillary adenocarcinomas were classified as the differentiated type, and poorly differentiated adenocarcinomas and signet-ring cell carcinomas were classified as the undifferentiated type. Mucinous adenocarcinomas were classified depending on other predominant elements. Tumour stage and pathological classification were defined according to the [@bib11]. Postoperative adjuvant chemotherapy was given to 51 patients with pathological T2--T4 tumours or lymph node metastasis. Among these 51 patients, 25 were treated with tegafur, 5-chloro-2,4-dihydroxypyridine, and oxonic acid (S1), 11 were treated with tegafur and uracil (UFT), 8 were treated with S1+docetaxel, 6 were treated with S1+irinotecan, and 1 was treated with S1+paclitaxel. The median follow-up time was 68 months (range: 1--97). A total of 22 patients died of GC-related causes during the study period. Peritoneal, lymphatic, and haematogenous recurrences occurred in 17, 8, and 9 cases, respectively. Written informed consent was obtained from all patients in accordance with the local ethical guidelines. The study was approved by the Institutional Review Board of the Shiga University of Medical Science.

Pathological examination
------------------------

Formalin-fixed, paraffin-embedded tissue blocks of the resected GC specimens were cut into 3-*μ*m-thick sections, deparaffinised, and rehydrated. Each section was stained with haematoxylin and eosin and then used for immunostaining. Immunohistochemical analyses were performed using an autostainer (Benchmark XT System; Ventana Medical Systems, Tucson, AZ, USA) according to the manufacturer\'s instructions. The following primary antibodies were used: primary antibodies against CD44s (H-CAM, 1 : 200 dilution; Novocastra Laboratories Ltd, Newcastle upon Tyne, UK), CD44v6 (VFF-18, 1 : 500 dilution; Abcam, Cambridge, UK), and CD44v9 (RV3, 1 : 5000 dilution; Cosmo Bio, Tokyo, Japan). Lymph nodes were used as the positive control for CD44s expression, and skin tissue was used as the positive control for CD44v6 and CD44v9 expression ([@bib22]). The negative control was evaluated by substituting the primary antibodies with similarly diluted non-immunised mouse serum. Immunostaining examinations were assessed independently by two pathologists blinded to the clinical or pathological features. When there were discrepancies, a final decision was established by reassessment using a double-headed microscope.

The ITF was evaluated at the deepest invasive section of the tumour ([@bib20]). CD44s, CD44v6, and CD44v9 expression was semiquantitatively analysed in whole-tumour tissue sections or at the ITF as the percentage of positive tumour cells. The percentage of positive tumour cells was evaluated in low-power fields (× 40) in the whole-tumour section; subsequently, positive membrane staining of the tumour cells was confirmed at × 100 magnification. A result was defined as positive when \>5% of cancer cells were positively stained and negative when \<5% of the cancer cells were positively stained. This cut-off value of 5% was consistent with that used in the previous reports ([@bib35]; [@bib16]; [@bib18]; [@bib30]). Tumour and stromal cells were identified based on the morphological features of the positive cells. When it was not clear whether positive cells were tumour cells or stromal cells using morphological methods, especially for poorly differentiated adenocarcinomas, immunostaining for cytokeratin (AE1/AE3, 1:10 dilution; Abcam, Cambridge, UK) was combined with morphological methods.

CD44 expression, initial recurrence pattern, and survival
---------------------------------------------------------

Initial recurrence patterns, based on the first recurrent lesion detected during postoperative follow-up, were determined using computed tomography at intervals of at least 6 months. Recurrence patterns were classified into three types; peritoneal, lymphatic, and haematogenous (i.e., liver, lung, brain, and bone metastasis). Disease-specific survival was calculated from the date of gastric surgery to either the date of death from GC or the date of the last follow-up.

Statistical analysis
--------------------

Univariate and multivariate analyses were performed using the Cox proportional hazards model to evaluate the associations between clinical covariates and disease-specific survival. Variables associated with survival with *P*\<0.05 in a univariate analysis were used for a multivariate analysis. Kaplan--Meier survival curves were constructed to compare patients with positive and negative CD44 expression. Significant differences were determined using the log-rank test. Associations of clinicopathological variables with CD44s, CD44v6, or CD44v9 expression were evaluated using the *χ*^2^-test or Fisher\'s exact test, as appropriate. Variables that showed differences at *P*\<0.10 were included in the multivariate logistic regression analyses. Cumulative incidence rates were calculated to evaluate the associations between initial recurrence patterns and CD44s, CD44v6, or CD44v9 expression. The cumulative incidence of each recurrence type was estimated using the competing-risk method, in which death from other causes was considered a competing risk. Comparisons between patients with positive and negative CD44 expression were performed using the Gray test. All *P*-values were two-sided, and the significance level was set at *P*\<0.05. Statistical analyses, except the Gray test, were performed using SPSS 22.0 (SPSS Inc., Chicago, IL, USA). Gray tests were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria).

Results
=======

Expression of CD44 isoforms in GC
---------------------------------

Patient and tumour characteristics are summarised in [Table 1](#tbl1){ref-type="table"}. Positive staining was observed for CD44s in 27 (22.0%) or 13 (10.6%) of the GC patients, positive staining for CD44v6 in 108 (87.8%) or 79 (64.2%) GC patients, and positive for CD44v9 in 72 (58.5%) or 47 (38.2%) GC patients in whole-tumour tissue sections or at the ITF, respectively. The immunohistochemical staining patterns of CD44s, CD44v6, and CD44v9 in whole-tumour sections and at the ITF of GC patients are shown in [Figure 1](#fig1){ref-type="fig"}. Membranous immunoreactivity was observed for CD44s, CD44v6, and CD44v9.

CD44 isoform expression and patient outcome
-------------------------------------------

To evaluate the prognostic potential of the presence of cancer stem-like cells at the ITF, we examined the relationship between CD44 isoform expression in whole-tissue sections or at the ITF and disease-specific survival ([Table 2](#tbl2){ref-type="table"}). A univariate Cox analysis showed that stage (hazard ratio (HR)=6.84; 95% confidence interval (CI), 2.67--17.54; *P*\<0.0001), blood vessel invasion (HR=12.5; 95% CI, 1.67--90.90; *P*=0.014), tumour size \>5 cm (HR=4.18; 95% CI, 1.63--10.75; *P*=0.003), CD44v9 expression in whole-tissue sections (HR=2.87; 95% CI, 1.06--7.75; *P*=0.039), CD44s expression at the ITF (HR=6.80; 95% CI, 2.73--16.95; *P*\<0.0001), CD44v6 expression at the ITF (HR=4.15; 95% CI, 1.23--14.08; *P*=0.022), and CD44v9 expression at the ITF (HR=4.65; 95% CI, 1.89--11.49; *P*=0.001) were associated with disease-specific survival. These results suggest that CD44 isoform expression at the ITF was a strong prognostic factor for GC. Furthermore, a multivariate Cox analysis revealed that CD44s expression at the ITF was a poor independent prognostic factor (HR=3.13; 95% CI, 1.09--9.01; *P*=0.035).

Kaplan--Meier survival curves according to the expression of each CD44 isoform at the ITF are shown in [Figure 2](#fig2){ref-type="fig"}. Patients with CD44s-, CD44v6-, or CD44v9-positive expression at the ITF showed significantly poorer survival than those with negative expression (*P*\<0.0001, *P*=0.013, and *P*=0.0002, respectively) ([Figure 2A--C](#fig2){ref-type="fig"}).

Predictive model for survival
-----------------------------

To generate a detailed predictive model for patients with GC surgery, we stratified patients based on the expression of each CD44 isoform at the ITF ([Figure 2D](#fig2){ref-type="fig"}). There were significant differences in survival among the four groups of patients: patients with negative expression for all CD44 isoforms (all-negative) (*n*=41), patients with positive expression for one CD44 isoform (single-positive) (*n*=38), patients with positive expression for two CD44 isoforms (double-positive) (*n*=31), and patients with positive expression for all CD44 isoforms (all-positive) (*n*=13) (*P*\<0.0001). The all-positive group showed the worst survival, that is, a 51.9% 5-year survival rate; the double-positive and single-positive groups showed 73.7% and 90.8% 5-year survival rates, respectively, and the all-negative group showed the best 5-year survival rate, that is, 97.4%. This stratified model based on the number of the CD44 isoforms detected predicts GC patient survival.

CD44 expression at the ITF and clinicopathological features
-----------------------------------------------------------

To clarify the factors affecting the presence of cancer stem-like cells at the ITF, we examined the correlation between conventional clinicopathological variables and CD44 isoform expression at the ITF. Univariate analyses revealed that CD44s expression at the ITF was not correlated with any clinicopathological variables ([Table 3a](#tbl3){ref-type="table"}). However, CD44v6 expression at the ITF was significantly correlated with the depth of tumour invasion (*P*=0.004), lymphatic invasion (*P*=0.005), and blood vessel invasion (*P*=0.011) ([Table 3b](#tbl3){ref-type="table"}). CD44v9 expression at the ITF was significantly correlated with tumour size (*P*=0.036) ([Table 3c](#tbl3){ref-type="table"}). However, according to a subsequent multivariate logistic regression analysis, no independent clinicopathological factors were associated with the expression of any CD44 isoform at the ITF.

CD44 expression at the ITF and recurrence
-----------------------------------------

We examined whether the expression of each CD44 isoform at the ITF was associated with recurrence after surgery for resectable GC. As summarised in [Table 4](#tbl4){ref-type="table"}, the cumulative recurrence rate at 5 years for each recurrence type was significantly higher in patients with CD44s-positive expression at the ITF than in patients with CD44s-negative expression at the ITF (peritoneal recurrence: 43.4%, 95% CI, 14.1--70.0% *vs* 5.8% 95% CI, 2.4--11.5%, *P*\<0.001; lymphatic recurrence: 51.3%, 95% CI, 12.1--80.9% *vs* 4.3%, 95% CI, 1.4--10.0%, *P*\<0.001; haematogenous recurrence: 29.4%, 95% CI, 5.4--59.7% *vs* 6.2% 95% CI, 2.5--12.2%, *P*=0.008). The cumulative peritoneal recurrence rate at 5 years was significantly higher in patients with CD44v6- or CD44v9-positive expression at the ITF than in those with negative expression (CD44v6 expression: 13.8%, 95% CI, 7.0--22.8% *vs* 2.4%, 95% CI, 0.2--11.2%, *P*=0.007; CD44v9 expression: 21.2%, 95% CI, 10.3--34.6% *vs* 2.9% 95% CI, 0.5--9.0%, *P*=0.041).

Discussion
==========

The results of this study showed that the presence of CD44-positive cancer stem-like cells at the ITF, independent of any conventional clinicopathological factors, is strongly correlated with poor survival of patients with resectable GC.

Cancer stem cells are a malignant subset found in hierarchically organised tumours and are capable of tumour initiation, self-renewal, and differentiation to the bulk of non-tumorigenic cancer cells. CD44 is a CSC surface marker in several cancers, including GC ([@bib1]; [@bib5]; [@bib6]; [@bib23]). Furthermore, in GC, CD44 variant isoforms have recently been reported to affect tumour initiation and cancer cell maintenance ([@bib9]), and may play a functional role in the protection of CSCs from high levels of ROS in the tumour microenvironment ([@bib8]). Several studies have reported that CD44 isoform expression in GC suggests a poor prognosis ([@bib28]; [@bib4]; [@bib32]); however, most studies of CSC marker expression in tumours assess the intensity of expression or proportion of cells expressing CSC markers using whole-tumour sections or tissue microarrays. The ITF, the deepest and most invasive area of the tumour, has been reported to contain useful prognostic information. In addition, various critical molecular events that regulate tumour proliferation, adhesion/migration, and angiogenesis occur in the ITF ([@bib2]; [@bib17]; [@bib21]). Accordingly, the ITF is mainly responsible for the clinical behaviour of the tumour ([@bib12]; [@bib25]). However, it is not clear whether the presence of CSCs at the ITF has clinical significance. In our study, CD44v9 expression in the whole-tumour sections was associated with survival, and the expression of all tested CD44 isoforms at the ITF was strongly associated with survival (CD44s: *P*\<0.00001, CD44v6: *P*=0.013, CD44v9: *P*=0.0002). These findings show that CD44-positive cancer stem-like cells at the ITF are more important prognostic factors than those in whole-tumour sections. Moreover, a multivariate logistic regression analysis showed that the expression of each CD44 isoform at the ITF was independent of conventional clinicopathological factors, suggesting that the expression of CD44 isoforms at the ITF is a distinctive prognostic factor. Additional studies are needed to reveal the association between the expression of CD44 isoforms and molecular or morphological changes in tumours at the ITF.

Epithelial-mesenchymal transition (EMT) is an important step in cancer invasion and metastasis ([@bib31]; [@bib27]). A switch from CD44v to CD44s is essential for EMT and tumour progression in breast cancer ([@bib3]). Furthermore, the ratio of vimentin/E-cadherin mRNA expression is significantly correlated with the CD44s/CD44v9 ratio in colorectal cancer, indicating that CD44 switching might induce EMT ([@bib14]). These findings suggest that CD44s confers mesenchymal properties, unlike other CD44-variants, and is associated with metastasis. Our data also showed that CD44s expression at the ITF is associated with peritoneal, lymphatic, and haematogenous recurrences, suggesting that CD44s-expressing cancer stem-like cells at the ITF are likely to metastasise in various directions. Moreover, CD44s expression was also recognised an independent prognostic factor. These findings support the hypothesis that CD44s switching affects EMT and metastasis in GC; however, experimental verification is still needed to conclusively evaluate the hypothesis.

We recently observed cancer cells that disseminated into the peritoneal cavity during curative gastrectomy in GC; moreover, these cancer cells have proliferative and tumorigenic capacity, which could result in peritoneal metastasis ([@bib24]). We also recently confirmed the presence of disseminated CD44s-expressing cancer stem-like cells during gastrectomy (Murata *et al*, unpublished data). In addition, we detected viable, proliferative, and clustered cancer cells, including CD44s-expressing cancer stem-like cells, in remnant gastric lumens immediately before gastrointestinal reconstruction ([@bib15]). In this study, the presence of CD44s-expressing tumour cells at the invasive front of the gastric wall was significantly correlated with peritoneal recurrences and poor survival. Cancer stem-like cells may spill out easily during resection when they are present at the ITF; CD44s-positive cancer cells that have mesenchymal properties may easily leave the ITF of the gastric wall and disseminate into the peritoneal cavity.

When patients were classified based on the number of CD44 isoforms expressed at the ITF, we found that the prognosis was worse in patients expressing more CD44 isoforms. This result suggests that each CD44 isoform in GC may have a distinct function. GC frequently exhibits marked histological heterogeneity with various differentiated cancer cells, and these might be produced by different undifferentiated cells with the properties of each CSC. Therefore, the functional role of each CD44 isoform in the tumour differentiation pathway, heterogeneity, and therapeutic resistance should be elucidated in the future. All patients with CD44s-positive cells in this study also had CD44v6- and CD44v9-positive cells at the ITF, and GC patients with CD44s-positive cells at the ITF had the worst prognosis in the predictive model for survival. The number of CD44 isoforms expressed was an indicator of patient outcome. In particular, the all-negative group showed the best survival among all predictive model groups. These findings suggest that both the expression of CD44s itself and the number of CD44 isoforms expressed have prognostic value in GC patients. From a clinical perspective, patients with positive expression for all CD44 isoforms at the ITF have a very poor prognosis, suggesting the need for more intensive adjuvant chemotherapy. Patients with negative expression of all CD44 isoforms at the ITF have extremely good outcomes, suggesting that adjuvant chemotherapy is not necessary after gastrectomy. To verify the utility of these biomarkers, that is, CD44 isoforms, at the ITF for making treatment decisions, clinical studies are needed.

In conclusion, the presence of CD44-expressing cancer stem-like cells at the ITF was significantly associated with poor survival in GC patients, indicating that CD44 isoforms are promising biomarkers for GC.
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![**CD44s, CD44v6, and CD44v9 expression in primary GC by IHC staining.** Representative images from three cases for the expression of each CD44 isoform are shown. (**A** and **D**), (**B** and **E**), and (**C** and **F**) are from the same patient. (**A**) Positive staining for CD44s both in whole tumour sections and at the ITF in GC with serosal exposure. (original magnification: × 40); (**B**) Positive staining for CD44v6 at the mucosal layer, but negative staining at the ITF of submucosal invasive GC. (**C**) Negative staining for CD44v9 in the surface layer, but positive staining at the ITF of muscularis propria invasive GC. (original magnification: × 40). In the high-power field, the expression of each CD44 isoform was identified along the membrane of cancer cells (**D**--**F**). (original magnification: × 200). Abbreviations: CD44s=CD44 standard isoform; CD44v6=CD44 variant isoform 6; CD44v9=CD44 variant isoform 9; GC=gastric cancer; IHC=immunohistochemistry; ITF=invasive tumour front.](bjc2016401f1){#fig1}

![**Disease-specific survival calculated by the Kaplan---Meier method in patients who underwent gastrectomy for resectable gastric cancer (GC).** (**A**) disease-specific survival in patients with or without CD44s expression at the invasive tumour front (ITF); (**B**) disease-specific survival in patients with or without CD44v6 expression at the ITF; (**C**) disease-specific survival in patients with or without CD44v9 expression at the ITF; (**D**) disease-specific survival in patients with the expression of more than one CD44 isoforms at the ITF; all-negative: patients who stained negative for all the CD44 isoforms at the ITF; single-positive: patients showing positive staining for one CD44 isoform at the ITF; double-positive: patients showing positive staining for two CD44 isoforms at the ITF; all-positive: patients showing positive staining for all the CD44 isoforms at the ITF.](bjc2016401f2){#fig2}

###### Characteristics of patients with gastric cancer

  **Patients**                       (***n*****=123)**
  --------------------------------- -------------------
  Age(median, range) (years)            70 (38--91)
  Gender                                      
   Male                                 83 (67.5%)
   Female                               40 (32.5%)
  Tumour invasion                             
   pT1 (SM)                             53 (43.1%)
   pT2 (MP)                              12 (9.8%)
   pT3 (SS)                             26 (21.1%)
   pT4a (SE)                            31 (25.2%)
   pT4b (SI)                             1 (0.8%)
  LN metastasis                               
   pN0                                  70 (56.9%)
   pN1                                  19 (15.4%)
   pN2                                  18 (14.6%)
   pN3                                  16 (13.0%)
  pStage                                      
   I                                    60 (48.8%)
   II                                   23 (18.7%)
   III                                  29 (23.6%)
   IV                                    11 (8.9%)
  Lymphatic invasion                          
   Absent                               32 (26.0%)
   Present                              91 (74.0%)
  Blood vessel invasion                       
   Absent                               41 (33.3%)
   Present                              82 (66.7%)
  CD44s in whole-tumour section               
   Negative                             96 (78.0%)
   Positive                             27 (22.0%)
  CD44v6 in whole-tumour section              
   Negative                             15 (12.2%)
   Positive                             108 (87.8%)
  CD44v9 in whole-tumour section              
   Negative                             51 (41.5%)
   Positive                             72 (58.5%)
  CD44s at invasive tumour front              
   Negative                             110 (89.4%)
   Positive                             13 (10.6%)
  CD44v6 at invasive tumour front             
   Negative                             44 (35.8%)
   Positive                             79 (64.2%)
  CD44v9 at invasive tumour front             
   Negative                             76 (61.8%)
   Positive                             47 (38.2%)

Abbreviations: CD44s=CD44 standard isoform; CD44v6=CD44 variant isoform 6; CD44v9=CD44 variant isoform 9; LN=lymph node.

pT1 (SM): tumour invades the submucosa.

pT2 (MP): tumour invades the muscularis propria.

pT3 (SS): tumour invades the subserosa.

pT4a (SE): tumour invasion is contiguous with or extends beyond the serosa.

pT4b (SI): tumour invades adjacent structures.

pN0: no regional lymph node metastasis.

pN1: metastasis in 1--2 regional lymph nodes.

pN2: metastasis in 3--6 regional lymph nodes.

pN3: metastasis in 7 or more regional lymph nodes.

Eleven patients showed CY1, accordingly were classified as Stage IV.

###### Relationship between clinicopathological variables and disease-specific survival

                                                    **Univariate analysis**        **Multivariate analysis**                           
  ------------------------------------------------ ------------------------- ------------------------------------- ------------------- ----------------------------------
  **Gender**                                                                                                                           
  Male                                                   1 (reference)                                                                                  
  Female                                             0.711 (0.413--1.222)                    0.216                                                      
  **Age**                                                                                                                              
  \<65 years                                             1 (reference)                                                                                  
  ⩾65 years                                           1.404 (0.600--3.29)                    0.433                                                      
  **pStage**                                                                                                                           
  StageI/StageII                                         1 (reference)                                                1 (reference)                     
  StageIII/StageIV                                    6.84 (2.67--17.54)      \<0.0001[a](#t2-fn3){ref-type="fn"}   3.12 (0.75--12.9)                0.118
  **Lympatic invasion**                                                                                                                
  Negative                                               1 (reference)                                                                                  
  Positive                                            37.18 (0.875--1611)                    0.06                                                       
  **Blood vessel invasion**                                                                                                            
  Negative                                               1 (reference)                                                1 (reference)                     
  Positive                                            12.5 (1.67--90.90)       0.014[a](#t2-fn3){ref-type="fn"}     6.02 (0.72--50.0)                0.098
  **Tumour size**                                                                                                                      
  ⩽5 cm                                                  1 (reference)                                                1 (reference)                     
  \>5 cm                                               4.18(1.63--10.75)       0.003[a](#t2-fn3){ref-type="fn"}     1.13 (0.28--4.63)                0.291
  **Histological type**                                                                                                                
  Differentiated                                         1 (reference)                                                                                  
  Undifferentiated                                    2.13(0.917--4.923)                     0.079                                                      
  **CD44s expression in whole-tumour section**                                                                                         
  Negative                                               1 (reference)                                                                                  
  Positive                                             2.28 (0.96--5.45)                     0.063                                                      
  **CD44v6 expression in whole-tumour section**                                                                                        
  Negative                                               1 (reference)                                                                                  
  Positive                                            24.49 (0.09--6591)                     0.263                                                      
  **CD44v9 expression in whole-tumour section**                                                                                        
  Negative                                               1 (reference)                                                1 (reference)                     
  Positive                                             2.87 (1.06--7.75)       0.039[a](#t2-fn3){ref-type="fn"}     1.10 (0.21--5.78)                0.912
  **CD44s expression at invasive tumour front**                                                                                        
  Negative                                               1 (reference)                                                1 (reference)                     
  Positive                                            6.80 (2.73--16.95)      \<0.0001[a](#t2-fn3){ref-type="fn"}   3.13 (1.09--9.01)   0.035[a](#t2-fn3){ref-type="fn"}
  **CD44v6 expression at invasive tumour front**                                                                                       
  Negative                                               1 (reference)                                                1 (reference)                     
  Positive                                            4.15 (1.23--14.08)       0.022[a](#t2-fn3){ref-type="fn"}     1.35 (0.35--5.26)                0.667
  **CD44v9 expression at invasive tumour front**                                                                                       
  Negative                                               1 (reference)                                                1 (reference)                     
  Positive                                            4.65 (1.89--11.49)       0.001[a](#t2-fn3){ref-type="fn"}     2.51 (0.49--12.8)                0.292

Abbreviations: CD44s=CD44 standard isoform; CD44v6=CD44 variant isoform 6; CD44v9=CD44 variant isoform 9; CI=confidence interval; HR=hazard ratio.

Eleven patients showed CY1, accordingly were classified as Stage IV.

Statistically significant.

###### Relationship between CD44 isoform expression at the invasive tumour front and clinicopathological variables

  **(a)** **CD44s expression at invasive tumour front**                                           
  ------------------------------------------------------- ----------- ----------- ------- --- --- ---
  **Gender**                                                                                      
  Male                                                     10(12.0%)   73(88.0%)                    
  Female                                                    3(7.5%)    37(92.5%)   0.442            
  **Age**                                                                                         
  \<65 years                                               5(12.8%)    34(87.2%)                    
  ⩾65 years                                                 8(9.5%)    76(90.5%)   0.58             
  **Depth of invasion**                                                                           
  pT1/pT2                                                   6(9.2%)    59(90.8%)                    
  pT3/pT4                                                  7(12.1%)    51(87.9%)   0.609            
  **LN metastasis**                                                                               
  pN0                                                       5(7.1%)    65(92.9%)                    
  pN1/pN2/pN3                                              8(15.1%)    45(84.9%)   0.155            
  **Lympatic invasion**                                                                           
  Negative                                                  3(9.4%)    29(90.6%)                    
  Positive                                                 10(11.0%)   81(89.0%)   0.798            
  **Blood vessel invasion**                                                                       
  Negative                                                  2(4.9%)    39(95.1%)                    
  Positive                                                 11(13.4%)   71(866%)    0.147            
  **Tumour size**                                                                                 
  \<5 cm                                                    6(8.7%)    63(91.3%)                    
  ⩾5 cm                                                    7(13.0%)    47(87.0%)   0.423            
  **Histological type**                                                                           
  Differentiated                                            6(8.2%)    67(91.8%)                    
  Undifferentiated                                         7(14.0%)    43(86.0%)   0.306            

  **(b)** **CD44v6 expression at invasive tumour front**                                                                                   
  -------------------------------------------------------- ----------- ----------- ---------------------------------- ------ ------------- -------
  **Gender**                                                                                                                               
  Male                                                      51(61.4%)   32(38.6%)                                                              
  Female                                                    28(70.0%)   12(30.0%)                0.354                                         
  **Age**                                                                                                                                  
  \<65 years                                                25(64.1%)   14(35.9%)                                                              
  ⩾65 years                                                 54(64.3%)   30(35.7%)                0.984                                         
  **Depth of invasion**                                                                                                                    
  pT1/pT2                                                   34(52.3%)   31(47.7%)                                                              
  pT3/pT4                                                   45(77.6%)   13(22.4%)   0.004[a](#t3-fn2){ref-type="fn"}   2.4    0.77--7.52    0.131
  **LN metastasis**                                                                                                                        
  pN0                                                       40(57.1%)   30(42.9%)                                                              
  pN1/pN2/pN3                                               39(73.6%)   14(26.4%)                 0.06                 1.34   0.431--4.15   0.614
  **Lympatic invasion**                                                                                                                    
  Negative                                                  14(43.8%)   18(56.3%)                                                              
  Positive                                                  65(71.4%)   26(28.6%)   0.005[a](#t3-fn2){ref-type="fn"}   1.81   0.59--5.52     0.3
  **Blood vessel invasion**                                                                                                                
  Negative                                                  20(48.8%)   21(51.2%)                                                              
  Positive                                                  59(72.0%)   23(28.0%)   0.011[a](#t3-fn2){ref-type="fn"}   1.41   0.51--3.94    0.508
  **Tumour size**                                                                                                                          
  \<5 cm                                                    40(58.8%)   29(42.0%)                                                              
  ⩾5 cm                                                     39(72.2%)   15(27.8%)                0.118                                         
  **Histological type**                                                                                                                    
  Differentiated                                            44(60.3%)   29(39.7%)                                                              
  Undifferentiated                                          35(70.0%)   15(30.0%)                0.269                                         

  **(c)** **CD44v9 expression at invasive tumour front**                                                                                  
  -------------------------------------------------------- ----------- ----------- ---------------------------------- ------ ------------ -------
  **Gender**                                                                                                                              
  Male                                                      30(36.1%)   53(63.9%)                                                             
  Female                                                    17(42.5%)   23(57.5%)                0.497                                        
  **Age**                                                                                                                                 
  \<65 years                                                10(25.6%)   29(74.4%)                                                             
  ⩾65 years                                                 37(44.0%)   47(56.0%)                0.051                 2.07   0.87--4.89   0.099
  **Depth of invasion**                                                                                                                   
  pT1/pT2                                                   20(30.8%)   45(69.2%)                                                             
  pT3/pT4                                                   27(46.6%)   31(53.4%)                0.072                 1.23   0.43--3.48   0.701
  **LN metastasis**                                                                                                                       
  pN0                                                       23(32.9%)   47(67.1%)                                                             
  pN1/pN2/pN3                                               24(45.3%)   29(54.7%)                 0.16                                        
  **Lympatic invasion**                                                                                                                   
  Negative                                                  8(25.0%)    24(75.0%)                                                             
  Positive                                                  39(42.9%)   52(57.1%)                0.074                 1.38   0.46--4.17   0.569
  **Blood vessel invasion**                                                                                                               
  Negative                                                  14(34.1%)   27(65.9%)                                                             
  Positive                                                  33(40.2%)   49(59.8%)                0.512                                        
  **Tumour size**                                                                                                                         
  \<5 cm                                                    21(30.4%)   48(69.6%)                                                             
  ⩾5 cm                                                     26(48.1%)   28(51.9%)   0.036[a](#t3-fn2){ref-type="fn"}   1.57   0.59--4.15   0.365
  **Histological type**                                                                                                                   
  Differentiated                                            26(35.6%)   47(64.4%)                                                             
  Undifferentiated                                          21(42.0%)   29(58.0%)                0.474                                        

Abbreviations: CD44s=CD44 standard isoform; CD44v6=CD44 variant isoform 6; CD44v9=CD44 variant isoform 9; CI=confidence interval; LN=lymph node.

Statistically significant.

###### 5-year cumulative incidence of each recurrence pattern for GC patients with and without CD44 isoform expression at the invasive tumour front

                                  **CD44s expression at invasive tumour front**   **CD44v6 expression at invasive tumour front**   **CD44v9 expression at invasive tumour front**                                                                                                                         
  ------------------------------- ----------------------------------------------- ------------------------------------------------ ------------------------------------------------ -------------------- ------------------- ---------------------------------- --------------------- ------------------- ----------------------------------
  Peritoneal recurrence rate      43.4% (14.1--70.0%)                             5.8% (2.4--11.5%)                                \<0.001[a](#t4-fn2){ref-type="fn"}               13.8% (7.0--22.8%)   2.4% (0.2--11.2%)   0.007[a](#t4-fn2){ref-type="fn"}   21.2% (10.3--34.6%)   2.9% (0.5--9.0%)    0.041[a](#t4-fn2){ref-type="fn"}
  Lymphatic recurrence rate       51.3% (12.1--80.9%)                             4.3% (1.4--10.0%)                                \<0.001[a](#t4-fn2){ref-type="fn"}               11.0% (4.8--20.1%)   2.8% (0.2--12.8%)   0.108                              14.6% (5.2--28.6%)    4.6% (1.2--11.7%)   0.062
  Haematogenous recurrence rate   29.4% (5.4--59.7%)                              6.2% (2.5--12.2%)                                0.008[a](#t4-fn2){ref-type="fn"}                 8.7% (3.5--16.9%)    7.3% (1.8--18.1%)   0.719                              12.9% (4.6--25.6%)    5.7% (1.8--13.0%)   0.156

Abbreviations: CD44s=CD44 standard isoform; CD44v6=CD44 variant isoform 6; CD44v9=CD44 variant isoform 9; CI=confidence interval; GC=gastric cancer.

Statistically significant.
